Kinin-Kallikrein System

Overview

The kinin-kallikrein system (KKS) is a peptide-generating proteolytic cascade that produces kinins — short-lived vasoactive peptides with potent effects on vascular tone, inflammation, pain signaling, and coagulation. The principal effector peptides are bradykinin (a nonapeptide) and kallidin (lysyl-bradykinin, a decapeptide), both of which act through B1 and B2 kinin receptors to produce vasodilation, increased vascular permeability, smooth muscle contraction, and nociceptor activation.

The KKS intersects extensively with the renin-angiotensin system, the coagulation cascade, and the complement system, positioning it at a crossroads of cardiovascular regulation, innate immunity, and inflammatory signaling.

Components of the System

Kallikreins

Kallikreins are serine proteases that cleave kininogen substrates to release kinins. Two major forms exist:

Plasma kallikrein — circulates as the inactive zymogen prekallikrein, which is activated by Factor XIIa (Hageman factor) upon contact with negatively charged surfaces. Plasma kallikrein cleaves high-molecular-weight kininogen (HMWK) to release bradykinin. This pathway is also called the contact activation system and represents the intersection of the KKS with the intrinsic coagulation cascade.

Tissue kallikreins — a family of 15 serine proteases (KLK1-KLK15) expressed in diverse tissues including the kidney, salivary glands, pancreas, and sweat glands. Tissue kallikrein (KLK1) cleaves low-molecular-weight kininogen (LMWK) to release kallidin (Lys-bradykinin), which is subsequently converted to bradykinin by aminopeptidases.

Kininogens

Kininogens are the precursor proteins from which kinins are excised:

• High-molecular-weight kininogen (HMWK) — a 120 kDa plasma glycoprotein that serves as substrate for plasma kallikrein and also functions as a cofactor in the contact activation pathway
• Low-molecular-weight kininogen (LMWK) — a 68 kDa protein, primarily a substrate for tissue kallikreins

Both kininogens are produced by the liver and contain the bradykinin sequence within their structure.

Kinins

The bioactive kinin peptides include:

• Bradykinin (BK) — Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe-Arg (9 amino acids)
• Kallidin (Lys-BK) — Lys-Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe-Arg (10 amino acids)
• Des-Arg9-bradykinin — a metabolite formed by carboxypeptidase cleavage of bradykinin, which preferentially activates B1 receptors
• Des-Arg10-kallidin — the corresponding B1-preferring metabolite of kallidin

Kinin Receptors

B2 Receptor

The B2 receptor is constitutively expressed on endothelial cells, smooth muscle, sensory neurons, and epithelial cells throughout the body. It is a GPCR that couples primarily to Gq proteins. Activation triggers:

• Phospholipase C activation — producing inositol trisphosphate (IP3) and diacylglycerol (DAG)
• Endothelial nitric oxide synthase (eNOS) activation — releasing nitric oxide, which causes vasodilation
• Prostacyclin (PGI2) release — contributing to vasodilation and inhibition of platelet aggregation
• Increased vascular permeability — contraction of endothelial cells, widening intercellular junctions
• Nociceptor sensitization — lowering the threshold for pain signaling in sensory nerves

Bradykinin and kallidin are the primary endogenous B2 ligands. B2 receptor activation is responsible for the acute, rapid-onset effects of kinin release.

B1 Receptor

The B1 receptor is minimally expressed under normal conditions but is rapidly upregulated during tissue injury, inflammation, and infection — primarily through NF-kB-dependent transcription induced by cytokines (IL-1beta, TNF-alpha) and bacterial lipopolysaccharide. B1 receptor ligands are the des-Arg metabolites of bradykinin and kallidin.

B1 receptor signaling produces sustained inflammatory effects including:

• Prolonged vasodilation and edema
• Leukocyte recruitment
• Chronic pain sensitization
• Fibroblast proliferation

The inducible nature of B1 receptors makes them particularly relevant to chronic inflammatory conditions and has made them a target for anti-inflammatory drug development.

Kinin Degradation

Kinins are among the shortest-lived bioactive peptides, with a plasma half-life of approximately 15-30 seconds. Multiple enzymes contribute to their rapid inactivation:

• ACE (kininase II) — the same angiotensin-converting enzyme that generates angiotensin II is the principal bradykinin-degrading enzyme, cleaving the C-terminal Phe-Arg dipeptide. This dual role of ACE directly links the KKS to the renin-angiotensin system.
• Carboxypeptidase N (kininase I) — removes the C-terminal arginine, generating des-Arg metabolites that activate B1 receptors
• Neutral endopeptidase (NEP/neprilysin) — cleaves bradykinin at multiple sites
• Aminopeptidase P — cleaves the N-terminal Arg-Pro bond

The rapid degradation of kinins ensures that their effects remain localized and transient under normal conditions.

Cross-Talk with Other Systems

RAAS Intersection

The KKS and RAAS are intimately linked through ACE:

• ACE inhibitors (used to treat hypertension) block both angiotensin II production and bradykinin degradation
• The blood pressure-lowering effect of ACE inhibitors is partly attributed to increased bradykinin levels and consequent nitric oxide release
• ACE inhibitor-induced cough and angioedema are side effects mediated by bradykinin accumulation in the airways and submucosal tissues

Coagulation System

The contact activation pathway initiates both the KKS and the intrinsic coagulation cascade. Factor XII activation on negatively charged surfaces simultaneously generates Factor XIIa (initiating coagulation) and activates prekallikrein (initiating kinin generation). This connection links bradykinin release to vascular injury and thrombotic events.

Complement System

Activated kallikrein can cleave complement component C5, generating the anaphylatoxin C5a. This provides a direct link between the KKS and the complement system, amplifying inflammatory responses.

Clinical Relevance

Hereditary Angioedema

The most dramatic clinical manifestation of KKS dysregulation is hereditary angioedema (HAE), caused by deficiency or dysfunction of C1-inhibitor — a serine protease inhibitor that normally restrains both plasma kallikrein and Factor XIIa. Without adequate C1-inhibitor, uncontrolled kallikrein activity generates excessive bradykinin, causing episodes of severe, potentially life-threatening submucosal and subcutaneous edema. The approved therapeutic icatibant is a selective B2 receptor antagonist used to treat acute HAE attacks.

Inflammatory and Pain Research

The KKS is relevant to peptide research through:

• B1 and B2 receptor antagonists as potential anti-inflammatory agents
• Understanding bradykinin's role in post-injury edema and pain
• Cross-talk mechanisms between the KKS and other peptide cascades

Related Topics

• Bradykinin — the primary kinin effector peptide
• Icatibant — a synthetic B2 receptor antagonist
• Renin-Angiotensin System — linked via ACE
• Complement System — intersects via kallikrein-mediated C5 cleavage
• Nitric Oxide System — downstream mediator of bradykinin-induced vasodilation